NIKKEI 225
38,079.70 +117.90 (+0.31%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.59 -0.14 (-0.17%) GOLD FUTURES
2,394.20 -3.80 (-0.16%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
51,204.29 +1,638.05 (+3.30%)
Immix Biopharma, Inc. (IMMX)
After hours:
| Previous close | 2.5000 |
| Open | 2.5100 |
| Bid | 2.1700 x 100 |
| Ask | 2.3100 x 100 |
| Day's range | 2.2001 - 2.5500 |
| 52-week range | 1.4000 - 7.7500 |
| Volume | |
| Avg. volume | 286,411 |
| Market cap | 58.336M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.00 |
GlobeNewswireImmix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today
- GlobeNewswire
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th
- GlobeNewswire
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. “We are looking forward to this important multi-site clinical trial with NXC-201 CAR-T
